{"id":"NCT00101582","sponsor":"Swedish Orphan Biovitrum","briefTitle":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","officialTitle":"Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurrent Chemotherapy (RT/CT)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2007-09","completion":"2016-08","firstPosted":"2005-01-13","resultsPosted":"2014-09-15","lastUpdate":"2016-09-27"},"enrollment":188,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Mucositis","Solid Tumors","Stomatitis","Head and Neck Cancer","Squamous Cell Carcinoma"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"palifermin","otherNames":["Kepivance","Recombinant Human Keratinocyte Growth Factor (rHuKGF)"]},{"type":"DRUG","name":"cisplatin chemotherapy","otherNames":[]},{"type":"RADIATION","name":"Radiotherapy","otherNames":[]}],"arms":[{"label":"Palifermin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this research study is to test the safety and effectiveness of palifermin to determine if weekly doses can be safely administered to reduce the incidence (occurrence of), duration (length of time) and severity (amount of pain) of oral mucositis (painful sores in the mouth). Mucositis is a common side effect for patients receiving chemotherapy (cancer-killing drug) and radiotherapy (cancer-killing x-rays) for the treatment of head and neck cancer (HNC).","primaryOutcome":{"measure":"Number of Participants With Severe (Grade 3 or 4) Oral Mucositis","timeFrame":"Up to Week 15","effectByArm":[{"arm":"Placebo","deltaMin":62,"sd":null},{"arm":"Palifermin","deltaMin":51,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0410"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":null},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":25,"n":91},"commonTop":["Nausea","Constipation","Anaemia","Weight decreased","Vomiting"]}}